News Agency
Men's Weekly

First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat

  • Written by PR Newswire

STOCKHOLM, March 11, 2026 /PRNewswire/ -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for endometriosis. This milestone marks an important step toward a new treatment for the approximately 190 million...

Read more: First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat

The Role of Stainless Steel Suppliers in Australia’s Industry

Stainless steel has become a cornerstone of modern industry, valued for its strength, durability, and resistance to corrosion. From construction and manufacturing to kitchenware and medical equipment, stainless steel plays a vital role in countless applications. Central to this supply... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion